Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Share-based Compensation: 2023-2024

Historic Share-based Compensation for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $58.5 million.

  • Inhibrx Biosciences' Share-based Compensation rose 7.08% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 81.64%. This contributed to the annual value of $58.5 million for FY2024, which is 135.52% up from last year.
  • According to the latest figures from FY2024, Inhibrx Biosciences' Share-based Compensation is $58.5 million, which was up 135.52% from $24.8 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Share-based Compensation registered a high of $58.5 million during FY2024, and its lowest value of $24.8 million during FY2023.
  • Over the past 2 years, Inhibrx Biosciences' median Share-based Compensation value was $41.7 million (recorded in 2023), while the average stood at $41.7 million.
  • Data for Inhibrx Biosciences' Share-based Compensation shows a peak YoY spiked of 135.52% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Share-based Compensation (Yearly) stood at $24.8 million in 2023, then skyrocketed by 135.52% to $58.5 million in 2024.